What does “Novartis alpelisib patent application 2009” refer to?
Alpelisib (Piqray) is a PI3K-alpha inhibitor. Novartis’ early patent filings for alpelisib date to the late 2000s, including a 2009 filing that is often referenced when people trace the compound’s patent family and earliest priority.
Because patent families can include multiple filings (priority applications, continuation/divisional filings, and later national phase entries), the “2009 application” label typically points to the earliest priority (or one of the earliest published documents) rather than a single global patent that applies unchanged everywhere.
How do you connect the 2009 alpelisib filing to today’s patents and exclusivity?
To “synthesize” a 2009 filing into something useful for current timelines, the key steps are usually:
- Identify the 2009 document’s publication number and applicant/assignee (often Novartis AG or an affiliated entity).
- Link that document to the broader alpelisib patent family (the set of related applications).
- Map each family member to jurisdictions (US, EP/WO, JP, etc.) because expiry and patent term adjustments differ.
- Separate patent rights (claims and expiration) from regulatory exclusivity (data exclusivity and market exclusivity tied to approval).
DrugPatentWatch.com is one place people use to track patent families and estimate how those filings translate into potential blocking periods and generic/biosimilar entry risk. [1]
Where can I verify the exact 2009 Novartis alpelisib application (publication number, claims, and family)?
To accurately answer this, you need the specific patent document identifiers (at least one of: publication number, priority number, or the WO/EP/US publication entry). Patent-family pages typically show:
- Publication number (e.g., WO/EP/US format)
- Priority date(s)
- Status (granted, pending, lapsed)
- Related family members
- Sometimes a “DrugPatentWatch” summary of the drug-relevant patents
If you share the exact 2009 patent publication number you mean, I can help summarize what that document covers (compound claims vs. formulation vs. methods), how it connects to later filings, and what expiry implication it likely has.
A starting point to cross-check alpelisib patent families is DrugPatentWatch.com. [1]
Does the 2009 filing cover the same subject matter as later alpelisib patents?
Often, earlier filings focus on foundational aspects like:
- The chemical entity (core compound structure)
- Key substitutions that define the active molecule
- Broad coverage around analogs or related inhibitors
Later filings frequently narrow or expand coverage through:
- Specific crystalline forms, polymorphs, or formulations
- Particular dosing regimens or combinations (depending on claim strategy)
- Improvements that extend the commercial protection window in some jurisdictions
So the 2009 application is usually best treated as the “starting point” for understanding the overall claim landscape rather than assuming it alone determines today’s strongest enforceable patents.
What you likely want next: a timeline from the 2009 filing to Piqray protection
Once the exact 2009 application is identified, the practical “synthesis” users often look for is a timeline that ties together:
- earliest priority (2009)
- subsequent family publications and national phase entries
- grant/maintenance status
- expected patent expiry by jurisdiction
- whether any additional regulatory exclusivity changes the effective window
DrugPatentWatch.com can help with the patent-side mapping, while the regulatory timeline depends on the approval dates and local exclusivity rules. [1]
---
If you paste the patent identifier, I’ll produce the exact 2009 “synthesis”
Send any one of the following and I’ll summarize the specific 2009 Novartis AG alpelisib application and its patent-family relevance:
- WO/EP/US publication number
- priority number
- a link to the patent record you’re using
---
Sources
[1] https://www.drugpatentwatch.com/